Abstract
10599 Background: Gemcitabine with Docetaxel is active in soft tissue sarcoma. Doxorubicin is a standard agent for sarcoma with proven efficacy. The combination of Gemcitabine, Docetaxel and Doxorubicin has been studied, and is well tolerated and active in breast cancer and non-small cell lung cancer. This study assesses the safety profile and efficacy of Gemcitabine, Doxorubicin, and Docetaxel regimen in patients with advanced, metastatic and/or unresectable sarcoma. Methods: 31 patients with advanced unresectable/metastatic sarcomas who progressed through standard chemotherapy were enrolled with consent. Patients were treated with Gemcitabine 400 mg/m2, Doxorubicin 20 mg/m2, and Docetaxel 20 mg/m2 on days 1 and 8 of a 21 day cycle. Disease was assessed with RECIST 1.1 and median Progression Free Survival(PFS) and Response rates(RR) were calculated. Toxicity evaluation was done using NCI CTCAE 4.2. Results: All subjects had advanced metastatic disease and were treated with a median of 2 prior regimens(ra...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
